1.17
price down icon6.40%   -0.08
after-market Dopo l'orario di chiusura: 1.17
loading
Precedente Chiudi:
$1.25
Aprire:
$1.25
Volume 24 ore:
9,247
Relative Volume:
0.48
Capitalizzazione di mercato:
$3.14M
Reddito:
-
Utile/perdita netta:
$-4.69M
Rapporto P/E:
-0.5021
EPS:
-2.33
Flusso di cassa netto:
$-3.81M
1 W Prestazione:
-11.36%
1M Prestazione:
-9.02%
6M Prestazione:
-47.53%
1 anno Prestazione:
-49.79%
Intervallo 1D:
Value
$1.155
$1.25
Intervallo di 1 settimana:
Value
$1.155
$1.41
Portata 52W:
Value
$1.02
$3.50

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name
Nome
Lixte Biotechnology Holdings Inc
Name
Telefono
310 203 2902
Name
Indirizzo
248 ROUTE 25A, EAST SETAUKET
Name
Dipendente
4
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
LIXT's Discussions on Twitter

Confronta LIXT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LIXT
Lixte Biotechnology Holdings Inc
1.17 3.54M 0 -4.69M -3.81M -2.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Lixte Biotechnology Holdings Inc Borsa (LIXT) Ultime notizie

pulisher
May 20, 2025

Lixte Biotechnology Converts Preferred Stock to Common - TipRanks

May 20, 2025
pulisher
May 12, 2025

Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

LIXTE BIOTECHNOLOGY HOLDINGS, INC. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
Apr 19, 2025

Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com India

Apr 19, 2025
pulisher
Apr 18, 2025

Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com

Apr 18, 2025
pulisher
Apr 16, 2025

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 44.0% in March - Defense World

Apr 16, 2025
pulisher
Apr 11, 2025

SEC Form 424B4 filed by Lixte Biotechnology Holdings Inc. - Quantisnow

Apr 11, 2025
pulisher
Mar 31, 2025

LIXTE Launches New Study to Determine if Certain - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan

Mar 27, 2025
pulisher
Mar 24, 2025

Lixte Biotechnology Holdings Inc. (LIXT) reports earnings - Quartz

Mar 24, 2025
pulisher
Mar 14, 2025

Lixte Biotechnology revises sarcoma study agreement By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Lixte Biotechnology revises sarcoma study agreement - Investing.com

Mar 14, 2025
pulisher
Mar 11, 2025

Lixte Biotech ends sales agreement, explores funding options By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 10:35 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Lixte Biotech ends sales agreement, explores funding options - Investing.com

Mar 11, 2025
pulisher
Mar 10, 2025

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form - GlobeNewswire

Mar 10, 2025
pulisher
Mar 10, 2025

New Research Reveals Key Mechanism Behind LIXT's Cancer Drug LB-100 - StockTitan

Mar 10, 2025
pulisher
Feb 25, 2025

LIXTE Adds Northwestern University’s Lurie Cancer Center as - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial - StockTitan

Feb 25, 2025
pulisher
Feb 22, 2025

Lixte Biotechnology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia

Feb 22, 2025
pulisher
Feb 22, 2025

Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India

Feb 22, 2025
pulisher
Feb 15, 2025

Lixte Biotechnology Holdings, Inc. Announces Successful Closure of $1.05 Million Offering - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Lixte Biotechnology announces closing of $1.05M registered direct offering - Yahoo Finance

Feb 14, 2025
pulisher
Feb 13, 2025

LIXTE Biotechnology Announces Closing of $1.05 Million - GlobeNewswire

Feb 13, 2025
pulisher
Feb 13, 2025

Lixte Biotechnology Closes $1.1 Million Direct Offering -February 13, 2025 at 11:06 am EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

LIXTE Biotechnology Holdings, Inc. Completes Registered Direct Offering and Private Placement Raising Approximately $1.05 Million - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

LIXTE Secures Critical $1.05M Funding: Strategic Move Unlocks Next Growth Phase - StockTitan

Feb 13, 2025
pulisher
Feb 12, 2025

LIXTE Biotechnology announces $1.05M registered direct offering; shares fall - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 12, 2025
pulisher
Feb 11, 2025

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times

Feb 11, 2025
pulisher
Feb 11, 2025

LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener - StockTitan

Feb 11, 2025
pulisher
Feb 11, 2025

Lixte Biotechnology Holdings Inc Inc. (LIXT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Feb 11, 2025
pulisher
Feb 10, 2025

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - GlobeNewswire

Feb 10, 2025
pulisher
Jan 07, 2025

Lixte Biotechnology enters agreement for at-the-market stock sale - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Lixte Biotechnology Holdings, Inc. Enters into At-the-Market Sales Agreement with WallachBeth Capital, LLC - Defense World

Jan 07, 2025
pulisher
Dec 30, 2024

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World

Dec 30, 2024
pulisher
Dec 30, 2024

Lixte Biotechnology Holdings, Inc. Vice President and COO Resigns - Defense World

Dec 30, 2024
pulisher
Dec 29, 2024

Lixte Biotechnology announces executive departure By Investing.com - Investing.com Nigeria

Dec 29, 2024
pulisher
Dec 29, 2024

Lixte Biotechnology announces executive departure - Investing.com

Dec 29, 2024
pulisher
Dec 18, 2024

US Penny Stocks To Watch In December 2024 - Simply Wall St

Dec 18, 2024

Lixte Biotechnology Holdings Inc Azioni (LIXT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):